Evidence map›Paper›PMID 41282128›Full record

ArticleResearch square2025

Programmable conjugative CRISPR interference targeting genotoxin in the gut.

Brian Hamp, Hania Timek, Chengyuan Fang, Zongqi Wang, Amber E Haley, Maria Jennings, Collins I Chimezie, Noah Hutchinson, Zhihong Dong, Shannon McCollum and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Brian HampDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Hania TimekDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Chengyuan FangDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Zongqi WangDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Amber E HaleyDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Maria JenningsDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Collins I ChimezieProgram in Chemical Biology, Life Sciences Institute, University of Michigan, Ann Arbor, MI, 48109, United States.
Noah HutchinsonDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Zhihong DongDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.
Shannon McCollumCellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, 48109-5622, United States.
Saleh KhawaledKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, United States.
Yatrik M ShahDepartment of Internal Medicine, Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, MI, 48109, United States.ORCID 0000-0002-2487-4816
Omer YilmazKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, United States.ORCID 0000-0002-7577-4612
Jiahe LiDepartment of Biomedical Engineering, College of Engineering and School of Medicine, University of Michigan, Ann Arbor, MI, 48109, United States.ORCID 0000-0002-9889-8546

Funding

Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal CancerR01CA303150 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LI, JIAHE, SHAH, YATRIK M · 2025 to 2025
$2.9M
Enzymatic and genetic strategies for targeting disease-associated microbial metabolitesDP2GM154019 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li · 2023 to 2026
$2.3M
Targeting a human gut bacterial genotoxin via engineered commensal bacteriaR01CA299955 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li, Omer Yilmaz · 2025 to 2026
$1.2M
NCI NIH HHS R01 CA299955NCI NIH HHS R01 CA303150NIGMS NIH HHS DP2 GM154019
6 · The paper itself

Abstract

Among microbially derived metabolites that influence host disease, colibactin garners increasing attention for its roles in the rising incidence of early-onset colorectal cancer. Produced by

Identifiers

PMID41282128
PMCPMC12633163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.